SR 121463A, a potent and selective, orally active, nonpeptide vasopressin V2 receptor antagonist, has been characterized in several in vitro and in vivo models. This compound displayed highly competitive and selective affinity for V2 receptors in rat, bovine and human kidney (0.6 < or = Ki [nM] < or = 4.1). In this latter preparation, SR 121463A potently antagonized arginine vasopressin (AVP)-stimulated adenylyl cyclase activity (Ki = 0.26+/-0.04 nM) without any intrinsic agonistic effect. In autoradiographic experiments performed in rat kidney sections, SR 121463A displaced [3H]AVP labeling especially in the medullo-papillary region and confirmed that it is a suitable tool for mapping V2 receptors. In comparison, the nonpeptide V2 antagonist, OPC-31260, showed much lower affinity for animal and human renal V2 receptors and lower efficacy to inhibit vasopressin-stimulated adenylyl cyclase (Ki in the 10 nanomolar range). Moreover, OPC-31260 exhibited a poor V2 selectivity profile and can be considered as a V2/V1a ligand. In normally hydrated conscious rats, SR 121463A induced powerful aquaresis after intravenous (0.003-0.3 mg/kg) or oral (0.03-10 mg/kg) administration. The effect was dose-dependent and lasted about 6 hours at the dose of 3 mg/kg p.o. OPC-31260 had a similar aquaretic profile but with markedly lower oral efficacy. The action of SR 121463A was purely aquaretic with no changes in urine Na+ and K+ excretions unlike that of known diuretic agents such as furosemide or hydrochlorothiazide. In addition, no antidiuretic properties have been detected with SR 121463A in vasopressin-deficient Brattleboro rats. Thus, SR 121463A is the most potent and selective, orally active V2 antagonist yet described and could be a powerful tool for exploring V2 receptors and the therapeutical usefulness of V2 blocker aquaretic agents in water-retaining diseases.
C Serradeil-Le Gal, C Lacour, G Valette, G Garcia, L Foulon, G Galindo, L Bankir, B Pouzet, G Guillon, C Barberis, D Chicot, S Jard, P Vilain, C Garcia, E Marty, D Raufaste, G Brossard, D Nisato, J P Maffrand, G Le Fur
Title and authors | Publication | Year |
---|---|---|
The Biology of Vasopressin
S Sparapani, C Millet-Boureima, J Oliver, K Mu, P Hadavi, T Kalostian, N Ali, CM Avelar, M Bardies, B Barrow, M Benedikt, G Biancardi, R Bindra, L Bui, Z Chihab, A Cossitt, J Costa, T Daigneault, J Dault, I Davidson, J Dias, E Dufour, S El-Khoury, N Farhangdoost, A Forget, A Fox, M Gebrael, MC Gentile, O Geraci, A Gnanapragasam, E Gomah, E Haber, C Hamel, T Iyanker, C Kalantzis, S Kamali, E Kassardjian, HK Kontos, TB Le, D LoScerbo, YF Low, DM Rae, F Maurer, S Mazhar, A Nguyen, K Nguyen-Duong, C Osborne-Laroche, HW Park, E Parolin, K Paul-Cole, LS Peer, M Philippon, CA Plaisir, JP Marroquin, S Prasad, R Ramsarun, S Razzaq, S Rhainds, D Robin, R Scartozzi, D Singh, SS Fard, M Soroko, NS Motlagh, K Stern, L Toro, MW Toure, S Tran-Huynh, S Trépanier-Chicoine, C Waddingham, AJ Weekes, A Wisniewski, C Gamberi |
Biomedicines | 2021 |
Synthesis of Six-Membered Spiro Azacyclic Oxindole Derivatives via a One-Pot Process of Umpolung Allylation/Aza-Prins Cyclization
WC Jang, M Jung, HM Ko |
Organic letters | 2021 |
Cryo–electron microscopy structure of the antidiuretic hormone arginine-vasopressin V2 receptor signaling complex
J Bous, H Orcel, N Floquet, C Leyrat, J Lai-Kee-Him, G Gaibelet, A Ancelin, J Saint-Paul, S Trapani, M Louet, R Sounier, H Déméné, S Granier, P Bron, B Mouillac |
Science Advances | 2021 |
Recent Advances in N‐Heterocyclic Carbene Catalyzed Oxidative Cyclization for the Formation of Heterocycles
T Pavithra, ES Devi, CU Maheswari |
ASIAN J ORG CHEM | 2021 |
Stereoselective synthesis and applications of spirocyclic oxindoles
AJ Boddy, JA Bull |
Organic Chemistry Frontiers | 2021 |
“ADPKD-omics”:Determinants of Cyclic AMP Levels in Renal Epithelial Cells
YR Mehta, SA Lewis, KT Leo, L Chen, E Park, V Raghuram, CL Chou, CR Yang, H Kikuchi, S Khundmiri, B Poll, MA Knepper |
Kidney International | 2021 |
“ADPKD-omics”: Determinants of Cyclic AMP Levels in Renal Epithelial Cells
Mehta YR, Lewis SA, Leo KT, Chen L, Park E, Raghuram V, Chou CL, Yang CR, Kikuchi H, Khundmiri S, Poll B, Knepper MA |
Kidney International | 2021 |
Phosphoproteomic Identification of Vasopressin/cAMP/Protein Kinase A–Dependent Signaling in Kidney
K Salhadar, A Matthews, V Raghuram, K Limbutara, CR Yang, A Datta, CL Chou, MA Knepper |
Molecular pharmacology | 2020 |
Intramolecular Dehydrogenative Coupling Approach to 2‐Oxindoles Using Fe(OAc) 2 /NaI/Na 2 S 2 O 8
J Zhao, X Song, D Li, J Zhao, J Qu, Y Zhou |
European Journal of Organic Chemistry | 2020 |
Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation
T Fujiki, F Ando, K Murakami, K Isobe, T Mori, K Susa, N Nomura, E Sohara, T Rai, S Uchida |
Scientific Reports | 2019 |
Modulation of proteostasis and protein trafficking: a therapeutic avenue for misfolded G protein-coupled receptors causing disease in humans
A Ulloa-Aguirre, JA Janovick |
Emerging Topics in Life Sciences | 2019 |
Voltage-gated Sodium Channels: Structure, Function and Channelopathies
M Chahine |
2017 | |
Voltage-gated Sodium Channels: Structure, Function and Channelopathies
M Chahine |
2017 | |
Voltage-gated Sodium Channels: Structure, Function and Channelopathies
M Chahine |
2017 | |
Small-Molecule Modulation of Protein Homeostasis
GM Burslem, CM Crews |
Chemical Reviews | 2017 |
Heart Failure
J Bauersachs, J Butler, P Sandner |
Heart Failure | 2017 |
Ligand recognition properties of the vasopressin V2 receptor studied under QSAR and molecular modeling strategies
M Martínez-Archundia, B Colín-Astudillo, LM Moreno-Vargas, G Ramírez-Galicia, R Garduño-Juárez, O Deeb, MC Contreras-Romo, A Quintanar-Stephano, E Abarca-Rojano, J Correa-Basurto |
Chemical Biology & Drug Design | 2017 |
Dehydration effects of a V2 antagonist on endolymphatic hydrops in guinea pigs
N Egami, A Kakigi, T Takeda, T Yamasoba |
Hearing Research | 2016 |
N -Heterocyclic Carbene Catalytic [4 + 2] Cyclization of 3-Alkylenyloxindoles with Enals: γ-Carbon Activation for Enantioselective Assembly of Spirocarbocyclic Oxindoles
H Yao, Y Zhou, X Chen, P Zhang, J Xu, H Liu |
The Journal of Organic Chemistry | 2016 |
Oxidative Dearomatic Cyclization of N-Substituted Benzanilide Derivatives: Conformational Effect of Amide Groups on the Reaction
J Takayama, T Sakamoto, K Hayashi, M Xuan, M Suda, H Teramae, Y Shimano |
HETEROCYCLES | 2016 |
How genetic errors in GPCRs affect their function: Possible therapeutic strategies
H Stoy, VV Gurevich |
Genes & Diseases | 2015 |
Effect of Small Molecule Vasopressin V 1a and V 2 Receptor Antagonists on Brain Edema Formation and Secondary Brain Damage following Traumatic Brain Injury in Mice
SM Krieg, S Sonanini, N Plesnila, R Trabold |
Journal of Neurotrauma | 2015 |
Mass-spectrometry-based method for screening of new peptide ligands for G-protein-coupled receptors
CT Cologna, N Gilles, J Echterbille, M Degueldre, D Servent, E Pauw, L Quinton |
Analytical and Bioanalytical Chemistry | 2015 |
Functional Amyloid Signaling via the Inflammasome, Necrosome, and Signalosome: New Therapeutic Targets in Heart Failure
TL Parry, JH Melehani, MJ Ranek, MS Willis |
Frontiers in Cardiovascular Medicine | 2015 |
Actualización en neuroendocrinología
CV Artero |
2015 | |
Diastereoselective Synthesis of Six-Membered Carbocyclic Spirooxindoles via 6π-Electrocyclization of 3-Dienylidene-2- oxindoles
KH Kim, HR Moon, J Lee, J Kim, JN Kim |
Advanced synthesis & catalysis | 2015 |
Multicolor time-resolved Förster resonance energy transfer microscopy reveals the impact of GPCR oligomerization on internalization processes
O Faklaris, M Cottet, A Falco, B Villier, M Laget, JM Zwier, E Trinquet, B Mouillac, JP Pin, T Durroux |
The FASEB Journal | 2015 |
Cellular Endocrinology in Health and Disease
AA Bremer, WL Miller |
Cellular Endocrinology in Health and Disease | 2014 |
The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors: G protein-coupled receptors
SP Alexander, HE Benson, E Faccenda, AJ Pawson, JL Sharman, M Spedding, JA Peters, AJ Harmar |
British Journal of Pharmacology | 2013 |
Enantioselective synthesis of spiro[cyclohexane-1,3′-indolin]-2′-ones containing multiple stereocenters via organocatalytic Michael/aldol cascade reactions
AK Ghosh, B Zhou |
Tetrahedron Letters | 2013 |
Stereoselective syntheses of functionalized spirocyclopenteneoxindoles via triphenylphosphine-catalyzed [3+2] cycloaddition reactions
QF Zhou, XP Chu, FF Ge, C Li, T Lu |
Molecular Diversity | 2013 |
Seldin and Giebisch's The Kidney
CJ Cooper, LD Dworkin, WL Henrich |
Seldin and Giebisch's The Kidney | 2013 |
Synthesis of Six-Membered Spirocyclic Oxindoles with Five Consecutive Stereocenters in an Asymmetric Organocatalytic One-Pot Michael/Michael/Aldol Addition Sequence
B Zhou, Y Yang, J Shi, Z Luo, Y Li |
The Journal of Organic Chemistry | 2013 |
Global analysis of the effects of the V2 receptor antagonist satavaptan on protein phosphorylation in collecting duct
JD Hoffert, T Pisitkun, F Saeed, JL Wilson, MA Knepper |
American journal of physiology. Renal physiology | 2013 |
Downregulation of vasopressin V1A receptors and activation of mitogen-activated protein kinase in rat mesangial cells cultured under high-glucose conditions
A Tahara, J Tsukada, Y Tomura, T Yatsu, M Shibasaki |
Clinical and Experimental Pharmacology and Physiology | 2012 |
Effects of High Glucose on AVP-Induced Hyperplasia, Hypertrophy, and Type IV Collagen Synthesis in Cultured Rat Mesangial Cells
A Tahara, J Tsukada, Y Tomura, T Yatsu, M Shibasaki |
Endocrine Research | 2012 |
Endoplasmic Reticulum Enrollment in Alzheimer’s Disease
RJ Viana, AF Nunes, CM Rodrigues |
Molecular Neurobiology | 2012 |
Genetics and diagnosis of central diabetes insipidus
DG Bichet |
Annales d'Endocrinologie | 2012 |
Analogue-Based Drug Discovery III: FISCHER:DRUG ANALOGS III O-BK
K Kondo, H Ogawa |
Analogue-Based Drug Discovery III: FISCHER:DRUG ANALOGS III O-BK | 2012 |
Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics
M Manning, A Misicka, A Olma, K Bankowski, S Stoev, B Chini, T Durroux, B Mouillac, M Corbani, G Guillon |
Journal of Neuroendocrinology | 2012 |
Vaptans and hyponatremia in critical patients
D D'Auria, GZ Marinosci, GD Benedictis, O Piazza |
Translational medicine @ UniSa | 2012 |
Vaptans and Hyponatremia in Critical Patients
D D’Auria, GZ Marinosci, GD Benedictis, O Piazza |
Translational medicine @ UniSa | 2012 |
Subcellular Biochemistry
G Maya-Núñez, A Ulloa-Aguirre, JA Janovick, PM Conn |
Sub-cellular biochemistry | 2012 |
Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)
N Gassanov, N Semmo, M Semmo, AM Nia, U Fuhr, F Er |
European Journal of Clinical Pharmacology | 2011 |
G Protein-Coupled Receptors
|
British Journal of Pharmacology | 2011 |
Vasopressin regulates rat mesangial cell growth by inducing autocrine secretion of vascular endothelial growth factor
A Tahara, J Tsukada, Y Tomura, T Yatsu, M Shibasaki |
The Journal of Physiological Sciences | 2011 |
Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study
D Aronson, JG Verbalis, M Mueller, H Krum, A Alvarisqueta, J Bluguermann, RA Guerrero, L Howes, H Krum, A Sindone, G Decaux, A Soupart, DE Allaf, F Baillie, N Racine, S Logsetty, A Morales, F Gutierrez, N Gadsboll, C Dervenis, A Manolis, D Tsiftsis, T Forster, L Ujszaszy, C Farsang, D Aronson, S Efrati, D Freimark, D Zeltser, Z Gaciong, I Skoneczna, A Drzewiecki, P Miekus, M Piepiorka, L Providencia, C Fonseca, N Lousada, M Dorobantu, D Dimulescu, M Vintila, AG Dan, L Rotaru, B Minescu, D Zdrenghea, MM de Basson, JS Roos, A Roodt, G Wikstrom, ES Chung, SS Gottlieb, A Jain, DC Pan |
European Journal of Heart Failure | 2011 |
The potential role for lixivaptan in heart failure and in hyponatremia
HD Zmily, NS Khan, S Daifallah, JK Ghali |
Expert Opinion on Investigational Drugs | 2011 |
Vasopressin induces human mesangial cell growth via induction of vascular endothelial growth factor secretion
A Tahara, J Tsukada, Y Tomura, T Yatsu, M Shibasaki |
Neuropeptides | 2011 |
The Posterior Pituitary
DG Bichet |
The Pituitary | 2011 |
Williams Textbook of Endocrinology
DW Cooke, SA Divall, S Radovick |
Williams Textbook of Endocrinology | 2011 |
The Pituitary
X Bertagna, L Guignat, MC Raux-Demay, B Guilhaume, F Girard |
The Pituitary | 2011 |
Pharmacoperones: A New Therapeutic Approach for Diseases Caused By Misfolded G Protein-Coupled Receptors
A Ulloa-Aguirre, PM Conn |
Recent patents on endocrine, metabolic & immune drug discovery | 2011 |
Tolvaptan inhibits ERK-dependent cell proliferation, Cl − secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin
GA Reif, T Yamaguchi, E Nivens, H Fujiki, CS Pinto, DP Wallace |
American journal of physiology. Renal physiology | 2011 |
Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents
PT Veeraveedu, SS Palaniyandi, K Yamaguchi, Y Komai, RA Thandavarayan, V Sukumaran, K Watanabe |
Drug Discovery Today | 2010 |
An overview of satavaptan: a selective V2 receptor antagonist
J Farah, S Daifallah, H Zmily, JK Ghali |
Therapy | 2010 |
Organocatalytic Tandem Reaction to Construct Six-Membered Spirocyclic Oxindoles with Multiple Chiral Centres through a Formal [2+2+2] Annulation
K Jiang, ZJ Jia, S Chen, L Wu, YC Chen |
Chemistry - A European Journal | 2010 |
Vasopressin: A Review of Therapeutic Applications
NF Holt, KL Haspel |
Journal of Cardiothoracic and Vascular Anesthesia | 2010 |
Antagonistas del receptor de vasopresina: los vaptanes
C Villabona |
Endocrinología y Nutrición | 2010 |
xPharm: The Comprehensive Pharmacology Reference
A Vinh |
xPharm: The Comprehensive Pharmacology Reference | 2010 |
Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus
SA Ranadive, B Ersoy, H Favre, CC Cheung, SM Rosenthal, WL Miller, C Vaisse |
Clinical Endocrinology | 2009 |
cAMP-dependent chloride secretion mediates tubule enlargement and cyst formation by cultured mammalian collecting duct cells
R Montesano, H Ghzili, F Carrozzino, BC Rossier, E Féraille |
American journal of physiology. Renal physiology | 2009 |
Vasopressin and oxytocin
|
British Journal of Pharmacology | 2009 |
VASOPRESSIN STIMULATES THE PRODUCTION OF EXTRACELLULAR MATRIX BY CULTURED RAT MESANGIAL CELLS
A Tahara, J Tsukada, Y Tomura, T Suzuki, T Yatsu, M Shibasaki |
Clinical and Experimental Pharmacology and Physiology | 2008 |
Pharmacology of vasopressin antagonists
LC Costello-Boerrigter, G Boerrigter, JC Burnett |
Heart Failure Reviews | 2008 |
Non-peptide arginine-vasopressin antagonists: the vaptans
G Decaux, A Soupart, G Vassart |
The Lancet | 2008 |
Treatment of Hyponatremia
P Gross |
Internal Medicine | 2008 |
Vasopressin Antagonists in the Treatment of Water-Retaining Disorders
S Kumar, T Berl |
Seminars in Nephrology | 2008 |
Hyponatriämie und Vaptane
C Palm, P Gross |
Der Nephrologe | 2008 |
Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities
I Kim, W Xu, JC Reed |
Nature Reviews Drug Discovery | 2008 |
Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies
B Mouillac, M Manning, T Durroux |
Mini reviews in medicinal chemistry | 2008 |
Studies in Natural Products Chemistry
M Seki |
Studies in Natural Products Chemistry | 2008 |
Différence de concentration urinaire selon le sexe ou l’origine ethnique : implications possibles dans la susceptibilité variable à différentes pathologies rénales et cardiovasculaires
J Perucca, N Bouby, P Valeix, P Jungers, L Bankir |
Néphrologie & Thérapeutique | 2008 |
Identification of novel selective V2 receptor non-peptide agonists
AL Tredici, KE Vanover, AE Knapp, SM Bertozzi, NR Nash, ES Burstein, J Lameh, EA Currier, RE Davis, MR Brann, N Mohell, R Olsson, F Piu |
Biochemical Pharmacology | 2008 |
Sodium Excretion in Response to Vasopressin and Selective Vasopressin Receptor Antagonists
J Perucca, DG Bichet, P Bardoux, N Bouby, L Bankir |
Journal of the American Society of Nephrology : JASN | 2008 |
Effects of Novel Vasopressin Receptor Antagonists on Renal Function and Cardiac Hypertrophy in Rats with Experimental Congestive Heart Failure
B Bishara, H Shiekh, T Karram, I Rubinstein, ZS Azzam, N Abu-Saleh, S Nitecki, J Winaver, A Hoffman, ZA Abassi |
The Journal of pharmacology and experimental therapeutics | 2008 |
Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin
C Chassin, MW Hornef, M Bens, M Lotz, JM Goujon, S Vimont, G Arlet, A Hertig, E Rondeau, A Vandewalle |
Journal of Experimental Medicine | 2007 |
Small-Molecule Vasopressin-2 Receptor Antagonist Identified by a G-Protein Coupled Receptor “Pathway” Screen
B Yangthara, A Mills, V Chatsudthipong, L Tradtrantip, AS Verkman |
Molecular pharmacology | 2007 |
Effect of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy
A Tahara, J Tsukada, Y Tomura, T Suzuki, T Yatsu, M Shibasaki |
Vascular Pharmacology | 2007 |
Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin
C Chassin, MW Hornef, M Bens, M Lotz, JM Goujon, S Vimont, G Arlet, A Hertig, E Rondeau, A Vandewalle |
Journal of Experimental Medicine | 2007 |
Biological characterization of rodent and human vasopressin V 1b receptors using SSR-149415, a nonpeptide V 1b receptor ligand
CS Gal, D Raufaste, S Derick, J Blankenstein, J Allen, B Pouzet, M Pascal, J Wagnon, MA Ventura |
American Journal of Physiology - Regulatory, Integrative and Comparative Physiology | 2007 |
Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease
J Perucca, N Bouby, P Valeix, L Bankir |
American Journal of Physiology - Regulatory, Integrative and Comparative Physiology | 2007 |
Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus
JH Robben, M Sze, NV Knoers, PM Deen |
American journal of physiology. Renal physiology | 2007 |
Molecular Mechanisms of Antidiuretic Effect of Oxytocin
C Li, W Wang, SN Summer, TD Westfall, DP Brooks, S Falk, RW Schrier |
Journal of the American Society of Nephrology : JASN | 2007 |
Vasopressin receptor antagonists
A Greenberg, JG Verbalis |
Kidney International | 2006 |
Vasopressin & Oxytocin
SP Alexander, A Mathie, JA Peters |
British Journal of Pharmacology | 2006 |
Kinetic and Theoretical Studies of a Facile, One-Pot Preparation of a Spirocyclohexylindolinone Derivative
A Sánta-Csutor, Z Mucsi, Z Finta, C Gönczi, J Halász, É Csikós, I Hermecz |
European Journal of Organic Chemistry | 2006 |
Binding and Signal Transduction Characteristics of the Nonpeptide Vasopressin V<sub>1A</sub> Receptor-Selective Antagonist YM218 in Cultured Rat Mesangial Cells
A Tahara, J Tsukada, Y Tomura, T Kusayama, K Momose, N Taniguchi, T Suzuki, T Yatsu, M Shibasaki |
Pharmacology | 2006 |
Hyponatremia in the Neurosurgical Patient: Epidemiology, Pathophysiology, Diagnosis, and Management
JF Fraser, PE Stieg |
Neurosurgery | 2006 |
Vaptans and the Treatment of Water-Retaining Disorders
F Quittnat, P Gross |
Seminars in Nephrology | 2006 |
Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells
A Tahara, J Tsukada, Y Tomura, K Momose, T Suzuki, T Yatsu, M Shibasaki |
European Journal of Pharmacology | 2006 |
Vasopressin Antagonists as Aquaretic Agents for the Treatment of Hyponatremia
C Palm, F Pistrosch, K Herbrig, P Gross |
The American Journal of Medicine | 2006 |
Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats
M Takeuchi, JD Lee, H Shimizu, T Ueda |
International Journal of Cardiology | 2006 |
Hyponatremia in cirrhosis: clinical features and management
M Martín-Llahí, M Guevara, P Ginès |
Gastroentérologie Clinique et Biologique | 2006 |
Studies on the chemistry of thienoanellated O,N- and S,N-containing heterocycles. Part 30: Synthesis and pharmacological properties of thieno[2,3-b][1,4]thiazines with potential vasopressin receptor antagonistic activity
ME Galanski, T Erker, N Handler, R Lemmens-Gruber, M Kamyar, CR Studenik |
Bioorganic & Medicinal Chemistry | 2006 |
Pharmacological Chaperone Activity of SR49059 to Functionally Recover Misfolded Mutations of the Vasopressin V 1a Receptor
SR Hawtin |
The Journal of biological chemistry | 2006 |
Posttranscriptional control of aquaporin-2 abundance by vasopressin in renal collecting duct principal cells
U Hasler, S Nielsen, E Féraille, PY Martin |
American journal of physiology. Renal physiology | 2006 |
Regulation of UT-A1-mediated transepithelial urea flux in MDCK cells
O Fröhlich, JD Klein, PM Smith, JM Sands, RB Gunn |
American journal of physiology. Cell physiology | 2006 |
Probing the Existence of G Protein-Coupled Receptor Dimers by Positive and Negative Ligand-Dependent Cooperative Binding
L Albizu, MN Balestre, C Breton, JP Pin, M Manning, B Mouillac, C Barberis, T Durroux |
Molecular pharmacology | 2006 |
An Overview of SSR149415, a Selective Nonpeptide Vasopressin V1b Receptor Antagonist for the Treatment of Stress‐Related Disorders
Gal CS, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A |
CNS Drug Reviews | 2006 |
Influence of enantiomers of 1-naphthylalanine in position 2 of VAVP and dVAVP on their pharmacological properties
I Derdowska, A Prahl, W Kowalczyk, M Janecki, S Melhem, HI Trzeciak, B Lammek |
European Journal of Medicinal Chemistry | 2005 |
Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors
A Tahara, J Tsukada, Y Tomura, T Kusayama, K Wada, N Ishii, N Taniguchi, T Suzuki, T Yatsu, W Uchida, M Shibasaki |
Pharmacological Research | 2005 |
An Overview of SSR149415, a Selective Nonpeptide Vasopressin V1b Receptor Antagonist for the Treatment of Stress-Related Disorders
CS Gal, J Wagnon, B Tonnerre, R Roux, G Garcia, G Griebel, A Aulombard |
CNS Drug Reviews | 2005 |
Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist
J Tsukada, A Tahara, Y Tomura, T Kusayama, K Wada, N Ishii, N Taniguchi, T Suzuki, T Yatsu, W Uchida, M Shibasaki |
Vascular Pharmacology | 2005 |
Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure
K Wada, A Fujimori, U Matsukawa, Y Arai, K Sudoh, T Yatsu, M Sasamata, K Miyata |
European Journal of Pharmacology | 2005 |
High-Throughput Screening of G Protein-Coupled Receptor Antagonists Using a Bioluminescence Resonance Energy Transfer 1-Based β-Arrestin2 Recruitment Assay
FF Hamdan, M Audet, P Garneau, J Pelletier, M Bouvier |
Journal of biomolecular screening | 2005 |
An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders
Claudine Serradeil-Le Gal, Jean Wagnon 3rd, Bernard Tonnerre, Richard Roux, Georges Garcia, Guy Griebel, Alain Aulombard |
CNS Drug Reviews | 2005 |
Key Amino Acids Located within the Transmembrane Domains 5 and 7 Account for the Pharmacological Specificity of the Human V1b Vasopressin Receptor
S Derick, A Pena, T Durroux, J Wagnon, CS Gal, M Hibert, D Rognan, G Guillon |
Molecular Endocrinology | 2004 |
SSR126768A (4-Chloro-3-[(3 R )-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2- oxo-2,3-dihydro-1 H -indol-3-yl]- N -ethyl- N -(3-pyridylmethyl)-benzamide, Hydrochloride): A New Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor
CS Gal, G Valette, L Foulon, G Germain, C Advenier, E Naline, M Bardou, JP Martinolle, B Pouzet, D Raufaste, C Garcia, E Double-Cazanave, M Pauly, M Pascal, A Barbier, B Scatton, JP Maffrand, GL Fur |
The Journal of pharmacology and experimental therapeutics | 2004 |
Vasopressin-independent renal urinary concentration: Increased rBSC1 and enhanced countercurrent multiplication
M Michimata, K Mizukami, M Suzuki, I Kazama, Y Nakamura, K Suzuki, T Yanagisawa, Y Imai, S Sasaki, M Matsubara |
Kidney International | 2003 |
Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion
S Ishikawa, RW Schrier |
Clinical Endocrinology | 2003 |
Cyclic AMP is sufficient for triggering the exocytic recruitment of aquaporin-2 in renal epithelial cells
D Lorenz, A Krylov, D Hahm, V Hagen, W Rosenthal, P Pohl, K Maric |
EMBO reports | 2003 |
Disorders of body water homeostasis
JG Verbalis |
Best Practice & Research Clinical Endocrinology & Metabolism | 2003 |
Vasopressin-induced facilitation of adrenergic responses in the rat mesenteric artery is V1-receptor dependent
JO Streefkerk, M Pfaffendorf, PA van Zwieten |
Autonomic and Autacoid Pharmacology | 2003 |
Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management
V Arroyo, J Colmenero |
Journal of Hepatology | 2003 |
Vasopressin: a new target for the treatment of heart failure
CR Lee, ML Watkins, JH Patterson, W Gattis, CM O’Connor, M Gheorghiade, KF Adams |
American Heart Journal | 2003 |
Conformational analysis of four spiro[cyclohexane-1,3′-indolin]-2′-one derivatives
J Halász, B Podányi, A Sánta-Csutor, Z Böcskei, K Simon, M Hanusz, I Hermecz |
Journal of Molecular Structure | 2003 |
Distúrbios na secreção e ação do hormônio antidiurético
LA Naves, L Vilar, AC Costa, L Domingues, LA Casulari |
Arquivos brasileiros de endocrinologia e metabologia | 2003 |
Pancreatic vasopressin V 1b receptors: characterization in In-R1-G9 cells and localization in human pancreas
V Folny, D Raufaste, L Lukovic, B Pouzet, P Rochard, M Pascal, CS Gal |
American journal of physiology. Endocrinology and metabolism | 2003 |
Vasopressin Receptor Antagonists: Therapeutic Potential in the Management of Acute and Chronic Heart Failure
SD Russell, T DeWald |
American Journal Cardiovascular Drugs | 2003 |
Recent discovery and development of non-peptide vasopressin V2receptor agonists
K Kondo |
Expert Opinion on Therapeutic Patents | 2002 |
The Effects of Several Vasopressin Receptor Antagonists on Normal Intraocular Pressure and the Intraocular Distribution of Vasopressin Receptor Subtypes
A Naito, T Kurasawa, Y Ohtake, Y Toyoda, Y Ezure, K Koike, K Shigenobu |
Biological & Pharmaceutical Bulletin | 2002 |
Pharmacological characterization of F-180: a selective human V1avasopressin receptor agonist of high affinity
M Andrés, M Trueba, G Guillon |
British Journal of Pharmacology | 2002 |
Vasopressin-induced presynaptic facilitation of sympathetic neurotransmission in the pithed rat
JO Streefkerk, MJ Mathy, M Pfaffendorf, PA van Zwieten |
Journal of Hypertension | 2002 |
Effect of YM471, a nonpeptide AVP receptor antagonist, on human coronary artery smooth muscle cells
A Tahara, J Tsukada, Y Tomura, K Wada, T Kusayama, N Ishii, T Yatsu, W Uchida, N Taniguchi, A Tanaka |
Peptides | 2002 |
Pharmacological characterization of YM471, a novel potent vasopressin V1A and V2 receptor antagonist
J Tsukada, A Tahara, Y Tomura, K Wada, T Kusayama, N Ishii, M Aoki, T Yatsu, W Uchida, N Taniguchi, A Tanaka |
European Journal of Pharmacology | 2002 |
Arginine vasopressin modulates expression of neuronal NOS in rat renal medulla
PY Martin, M Bianchi, F Roger, L Niksic, E Féraille |
American journal of physiology. Renal physiology | 2002 |
Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites
D Guyader |
Hepatology | 2002 |
Characterization of (2 S ,4 R )-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1 H -indol-3-yl]-4-hydroxy- N , N -dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V 1b Receptor Antagonist
CS Gal, J Wagnon, J Simiand, G Griebel, C Lacour, G Guillon, C Barberis, G Brossard, P Soubrié, D Nisato, M Pascal, R Pruss, B Scatton, JP Maffrand, GL Fur |
The Journal of pharmacology and experimental therapeutics | 2002 |
NEPHROGENICDIABETESINSIPIDUS
JP Morello, DG Bichet |
Annual Review of Physiology | 2001 |
Treatment of severe hyponatremia
P Gross |
Kidney International | 2001 |
Effects of YM471, a nonpeptide AVP V1Aand V2receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells
J Tsukada, A Tahara, Y Tomura, W Ki, T Kusayama, N Ishii, T Yatsu, W Uchida, N Taniguchi, A Tanaka |
British Journal of Pharmacology | 2001 |
THEBASIC ANDCLINICALPHARMACOLOGY OFNONPEPTIDEVASOPRESSINRECEPTORANTAGONISTS
M Thibonnier, P Coles, A Thibonnier, M Shoham |
Annual Review of Pharmacology and Toxicology | 2001 |
A nonpeptide vasopressin V1a receptor antagonist, SR 49059, does not prevent cisplatin-induced emesis in piglets
L Grelot, V Girod, J Dapzol, JP Maffrand, CS Gal |
Fundamental and Clinical Pharmacology | 2001 |
An Overview of SR121463, a Selective Non-Peptide Vasopressin V2 Receptor Antagonist
CS Gal |
Cardiovascular Drug Reviews | 2001 |
Chronic exposure to vasopressin upregulates ENaC and sodium transport in the rat renal collecting duct and lung
C Nicco, M Wittner, A DiStefano, S Jounier, L Bankir, N Bouby |
Hypertension | 2001 |
Single Amino Acid Substitutions and Deletions That Alter the G Protein Coupling Properties of the V2 Vasopressin Receptor Identified in Yeast by Receptor Random Mutagenesis
I Erlenbach, E Kostenis, C Schmidt, CS Gal, D Raufaste, ME Dumont, MH Pausch, J Wess |
The Journal of biological chemistry | 2001 |
Selective blockade of vasopressin V2 receptors reveals significant V2‐mediated water reabsorption in Brattleboro rats with diabetes insipidus
B Pouzet, CS Gal, N Bouby, JP Maffrand, GL Fur, L Bankir |
Nephrology Dialysis Transplantation | 2001 |
Total Synthesis of SR 121463 A, a Highly Potent and Selective Vasopressin V 2 Receptor Antagonist
H Venkatesan, MC Davis, Y Altas, JP Snyder, DC Liotta |
The Journal of Organic Chemistry | 2001 |
Glomerular Injury and Tubular Loss in Adriamycin Nephrosis
B Javaid, JL Olson, TW Meyer |
Journal of the American Society of Nephrology : JASN | 2001 |
Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors
A Giełdoń, R Kaźmierkiewicz, R Slusarz, J Ciarkowski |
Journal of Computer-Aided Molecular Design | 2001 |
Vasopressin-induced von Willebrand factor secretion from endothelial cells: involvement of V2 receptors and cAMP
Jocelyne E. Kaufmann, Alexander Oksche, Claes B. Wollheim, Gabriele Gunther, Walter Rosenthal, Ulrich M. Vischer |
Journal of Clinical Investigation | 2000 |
Generation and phenotype of mouse strains harboring a nonsense mutation within the V2 vasopressin receptor coding sequence
June Yun, Torsten Schoneberg, Jie Liu, Angela Schulz, Carolyn A.Ecelbarger,Dominique Promeneur,Soren Nielson,Hui Sheng, Alexander Grinberg, Chu-xia Deng, Jurgen Wess |
Journal of Clinical Investigation | 2000 |
Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants
JP Morello, A Salahpour, A Laperrière, V Bernier, MF Arthus, M Lonergan, U Petäjä-Repo, S Angers, D Morin, DG Bichet, M Bouvier |
Journal of Clinical Investigation | 2000 |
Characterization of a novel nonpeptide vasopressin V2-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes
S Nakamura, Y Yamamura, S Itoh, T Hirano, K Tsujimae, M Aoyama, K Kondo, H Ogawa, T Shinohara, K Kan, Y Tanada, S Teramoto, T Sumida, S Nakayama, K Sekiguchi, T Kambe, G Tsujimoto, T Mori, M Tominaga |
British Journal of Pharmacology | 2000 |
Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells
A Tahara, J Tsukada, Y Tomura, K Wada, T Kusayama, N Ishii, T Yatsu, W Uchida, A Tanaka |
British Journal of Pharmacology | 2000 |
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [3H]-SR 121463
CS Gal, D Raufaste, E Double-Cazanave, G Guillon, C Garcia, M Pascal, JP Maffrand |
Kidney International | 2000 |
Vasopressin receptor antagonism - a therapeutic option in heart failure and hypertension
LM Burrell, J Risvanis, CI Johnston, M Naitoh, LC Balding |
Experimental Physiology | 2000 |
Nephrogenic diabetes insipidus
PM Deen, N Marr, EJ Kamsteeg, BW van Balkom |
Current Opinion in Nephrology and Hypertension | 2000 |
The treatment of hyponatraemia using vasopressin antagonists
P Gross, C Palm |
Experimental Physiology | 2000 |
Pharmacological chaperones: a new twist on receptor folding
JP Morello, M Bouvier, UE Petäjä-Repo, DG Bichet |
Trends in Pharmacological Sciences | 2000 |
Effect of SR121463, a Selective Non-Peptide Vasopressin V2Receptor Antagonist, in a Rabbit Model of Ocular Hypertension
F Lacheretz, A Barbier, CS Gal, PP Elena, JP Maffrand, GL Fur |
Journal of Ocular Pharmacology and Therapeutics | 2000 |
Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding
N Cotte, MN Balestre, A Aumelas, E Mahé, S Phalipou, D Morin, M Hibert, M Manning, T Durroux, C Barberis, B Mouillac |
European Journal of Biochemistry | 2000 |
Aquaretic and hormonal effects of a vasopressin V2 receptor antagonist after acute and long-term treatment in rats
C Lacour, G Galindo, F Canals, D Segondy, C Cazaubon, CS Gal, A Roccon, D Nisato |
European Journal of Pharmacology | 2000 |
Hyponatremia
HJ Adrogué, NE Madias |
New England Journal of Medicine | 2000 |
Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem
V Arroyo, W Jiménez |
Journal of Hepatology | 2000 |
Vasopressin V 2 -receptor-dependent regulation of AQP2 expression in Brattleboro rats
D Promeneur, TH Kwon, J Frøkiær, MA Knepper, S Nielsen |
American journal of physiology. Renal physiology | 2000 |
Polarized expression of the vasopressin V2 receptor in Madin-Darby canine kidney cells
B Andersen-Beckh, M Dehe, R Schulein, B Wiesner, C Rutz, U Liebenhoff, W Rosenthal, A Oksche |
Kidney International | 1999 |
Aquaretics
M Thibonnier |
Expert Opinion on Emerging Drugs | 1999 |
In vivo and in vitro characterisation of a nonpeptide vasopressin V1A and V2 receptor antagonist (YM087) in the rat
J Risvanis, M Naitoh, CI Johnston, LM Burrell |
European Journal of Pharmacology | 1999 |
Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells
A Tahara, M Saito, J Tsukada, N Ishii, Y Tomura, K Wada, T Kusayama, T Yatsu, W Uchida, A Tanaka |
European Journal of Pharmacology | 1999 |
PHARMACOLOGICAL PROFILE OF ORALLY ADMINISTERED YM087, A VASOPRESSIN ANTAGONIST, IN CONSCIOUS RATS
Y Tomura, A Tahara, J Tsukada, T Yatsu, W Uchida, YI Honda |
Clinical and Experimental Pharmacology and Physiology | 1999 |
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women
M Akerlund, T Bossmar, R Brouard, A Kostrzewska, T Laudanski, A Lemancewicz, CS Gal, M Steinwall |
BJOG: An International Journal of Obstetrics and Gynaecology | 1999 |
V1a- and V2-type vasopressin receptors mediate vasopressin-induced Ca2+ responses in isolated rat supraoptic neurones
L Gouzénes, N Sabatier, P Richard, FC Moos, G Dayanithi |
The Journal of Physiology | 1999 |
Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats
P Bardoux, H Martin, M Ahloulay, F Schmitt, N Bouby, MM Trinh-Trang-Tan, L Bankir |
Proceedings of the National Academy of Sciences | 1999 |
Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity
I Méchaly, F Laurent, K Portet, JJ Serrano, G Cros |
European Journal of Pharmacology | 1999 |
Comparison of vasopressin binding sites in human uterine and vascular smooth muscle cells
A Tahara, J Tsukada, N Ishii, Y Tomura, K Wada, T Kusayama, T Yatsu, W Uchida, A Tanaka |
European Journal of Pharmacology | 1999 |
Characterization of rodent liver and kidney AVP receptors: pharmacologic evidence for species differences
A Tahara, J Tsukada, N Ishii, Y Tomura, K Wada, T Kusayama, T Yatsu, W Uchida, A Tanaka |
Regulatory Peptides | 1999 |
Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: Study in vasopressin-deficient Brattleboro rats
P Bardoux, H Martin, M Ahloulay, F Schmitt, N Bouby, MM Trinh-Trang-Tan, L Bankir |
Proceedings of the National Academy of Sciences | 1999 |
7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): A potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist
K Kondo, H Ogawa, H Yamashita, H Miyamoto, M Tanaka, K Nakaya, K Kitano, Y Yamamura, S Nakamura, T Onogawa, T Mori, M Tominaga |
Bioorganic & Medicinal Chemistry | 1999 |
Neurologische Intensivmedizin
S Schwab, D Krieger, W Müllges, G Hamann, W Hacke |
1999 | |
V2-vasopressin receptor antagonists—mechanism of effect and clinical implications in hyponatraemia
C Palm, P Gross |
Nephrology Dialysis Transplantation | 1999 |
Hyponatremia in cirrhosis: From pathogenesis to treatment
P Gin�s, T Berl, M Bernardi, DG Bichet, G Hamon, W Jim�nez, JF Liard, PY Martin, RW Schrier |
Hepatology | 1998 |
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells
A Tahara, M Saito, T Sugimoto, Y Tomura, K Wada, T Kusayama, J Tsukada, N Ishii, T Yatsu, W Uchida, A Tanaka |
British Journal of Pharmacology | 1998 |
Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists
M Thibonnier |
Expert Opinion on Investigational Drugs | 1998 |
Binding Characteristics of YM087, an AVP Receptor Antagonist, in Rhesus Monkey Liver and Kidney Membranes
A Tahara, Y Tomura, K Wada, T Kusayama, J Tsukada, N Ishii, T Yatsu, W Uchida, A Tanaka |
Peptides | 1998 |
Stability of the vasopressin V2 receptor–adenylyl cyclase system in rat kidney
T Shen, J Laycock, Y Suzuki, N Defer, J Hanoune |
European Journal of Pharmacology | 1998 |
The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities
D Morin, N Cotte, MN Balestre, B Mouillac, M Manning, C Breton, C Barberis |
FEBS Letters | 1998 |
Acute effects of vasopressin V 2 -receptor antagonist on kidney AQP2 expression and subcellular distribution
BM Christensen, D Marples, UB Jensen, J Frøkiaer, D Sheikh-Hamad, M Knepper, S Nielsen |
American journal of physiology. Renal physiology | 1998 |
Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte
A Tahara, Y Tomura, K Wada, T Kusayama, J Tsukada, N Ishii, T Yatsu, W Uchida, A Tanaka |
Cardiovascular Research | 1998 |
Identification of Residues Responsible for the Selective Binding of Peptide Antagonists and Agonists in the V2 Vasopressin Receptor
N Cotte, MN Balestre, S Phalipou, M Hibert, M Manning, C Barberis, B Mouillac |
The Journal of biological chemistry | 1998 |
Vasopressin and Oxytocin
HH Zingg, CW Bourque, DG Bichet |
1998 | |
A Prospective Study of Patients with Lung Cancer and Hyponatremia of Malignancy
BE Johnson, JP Chute, J Rushin, J Williams, PT Le, D Venzon, GE Richardson |
American journal of respiratory and critical care medicine | 1997 |
Characterization and localization of leptin receptors in the rat kidney
C Serradeil-Le Gal, D Raufaste, G Brossard, B Pouzet, E Marty, J P Maffrand, G Le Fur |
FEBS Letters | 1997 |
Low urine flow reduces the capacity to excrete a sodium load in humans
G Choukroun, F Schmitt, F Martinez, TB Drüeke, L Bankir |
American Journal of Physiology - Regulatory, Integrative and Comparative Physiology | 1997 |
G Protein-Coupled Receptors
TP Iismaa, TJ Biden, J Shine |
1995 | |
Progress in Brain Research
DE van Epps, L Saland, C Taylor, RC Williams |
Progress in brain research | 1983 |